title: Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm.
authors.forename: Matthew
authors.initials: M
authors.lastname: Zibelman
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000401:mortality / Q000473:pathology; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004059:Diffusion of Innovation; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D057170:Translational Research, Biomedical / Q000639:trends; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000401:mortality / Q000473:pathology; D019459:Urothelium / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins